Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection

• Verfasst von: Miao, Zhijiang [VerfasserIn]
• Verfasst von: Zhang, Shaoshi [VerfasserIn]
• Verfasst von: Ou, Xumin [VerfasserIn]
• Verfasst von: Li, Shan [VerfasserIn]
• Verfasst von: Ma, Zhongren [VerfasserIn]
• Verfasst von: Wang, Wenshi [VerfasserIn]
• Verfasst von: Peppelenbosch, Maikel P [VerfasserIn]
• Verfasst von: Liu, Jiaye [VerfasserIn]
• Verfasst von: Pan, Qiuwei [VerfasserIn]
• Titel: Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection
• Verf.angabe: Zhijiang Miao, Shaoshi Zhang, Xumin Ou, Shan Li, Zhongren Ma, Wenshi Wang, Maikel P Peppelenbosch, Jiaye Liu, and Qiuwei Pan
• Jahr: 2020
• Jahr des Originals: 2019
• Umfang: 11 S.
• Teil: volume:221
• Teil: year:2020
• Teil: number:10
• Teil: month:05
• Teil: pages:1677-1687
• Teil: extent:11
• Fussnoten: Published online November 28, 2019 ; Gesehen am 31.03.2021
• Titel Quelle: Enthalten in: The journal of infectious diseases
• Ort Quelle: Oxford [u.a.] : Oxford Univ. Press, 1904
• Jahr Quelle: 2020
• Band/Heft Quelle: 221(2020), 10 vom: Mai, Seite 1677-1687
• ISSN Quelle: 1537-6613
• DOI: doi:10.1093/infdis/jiz633
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1752916646

Abstract

Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection.We conducted a meta-analysis with a random-effects model and performed data synthesis.The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63-1.00) among the general population and 13.02% (95% CI, 11.96-14.11) among HBV carriers, corresponding to 48-60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84-34.29), 25.77% (95% CI, 20.62-31.27), and 19.80% (95% CI, 10.97-30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65-5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79-8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average.Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment.